Laminar Pharma Shares First PFS Data for LAM561 in Glioblastoma Treatment
March 5, 2025
Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced optimistic results from its ongoing clinical trial evaluating